CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, today ...

Enhanced Genomics’ 3D multi-omics platform harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches Breakthrough demonstrates the ...

Agreement expands Active Motif's research genomics portfolio while supporting Arima's strategic focus on its clinical diagnostics platform CARLSBAD, Calif., July 6, 2026 /PRNewswire/ -- Active Motif, ...

Enhanced Genomics ('Enhanced'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has ...

Enhanc3D Genomics (‘Enhanced’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug ...

Oxford BioDynamics Plc (AIM: OBD, the Company), the 3D Genomics Company, announces that it has today granted a total of 1,008,068,322 options (“Options”) over its ordinary shares of 0.1 pence each ...

In particular, genome-wide association studies (GWAS) have pinpointed hundreds of genes associated with disease risk, enabling the development of drugs targeting a broad range of highly prevalent ...

The genome is more than a linear code; it is a dynamic structure whose three-dimensional folding dictates how genes are regulated. Traditional sequencing technologies capture base-level variation but ...

A great deal has changed since April 2003 when the human genome was first sequenced. Now, Enhanced Genomics (Cambridge, UK) has developed a 3D multi-omic profiling technology, GenLink, that combines ...

CARLSBAD, Calif., July 6, 2026 /PRNewswire/ -- Active Motif, a leading provider of epigenetics and multiomic solutions to mechanistic, translational, and clinical researchers, today announced an ...